Results 121 to 130 of about 121,953 (266)

Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota, David J. Grelotti, Tyler Nguyen, Walter H. Kaye, Skylar Swindle, Raymond Suhandynata, Spencer Seely, Megan E. Shott, Guido K. W. Frank   +8 more
wiley   +1 more source

Personalized Treatment Selection for Digital Eating Disorder Interventions: A Proof‐of‐Concept for the Personalized Advantage Index

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Although a range of evidence‐based treatments for eating disorders exist, treatment response varies substantially. The ability to match individuals to a treatment which they are most likely to benefit from may help improve treatment efficiency and therapeutic outcomes.
Zoe McClure, Matthew Fuller‐Tyszkiewicz, Mariel Messer, Jake Linardon   +3 more
wiley   +1 more source

Asiaticoside Attenuates Chronic Restraint Stress-Induced Hippocampal CA1 Neuronal Ferroptosis via Activating BDNF/Nrf2/GPX4 Signaling Pathway

Drug Design, Development and Therapy
An Zhou,1– 3 Hao-Yinghua Feng,4 Chu-Ning Fan,3 Jun Wang,3 Zhong-Yu Yuan,3 Guang-Hui Xu,5 Cheng-Fu Li,6 Wei-Feng Huang,1 Li-Tao Yi3,7,8 1Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Xiamen University, School of Medicine,
Zhou A, Feng HY, Fan CN, Wang J, Yuan ZY, Xu GH, Li CF, Huang WF, Yi LT   +8 more
doaj  

Benchmarking Generative Artificial Intelligence Against Human Judgment in Eating Disorder Case Recognition and Treatment Recommendations

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Generative AI is now used to access eating disorder (ED) information, yet the suitability of its outputs remains unclear. Using two vignettes, we evaluated generative AI's ability to accurately identify ED presentations and recommend appropriate care, while benchmarking its performance against published responses from human samples ...
Jake Linardon, Mariel Messer
wiley   +1 more source

Associations Between Microbial Depletion and Autonomic Dysregulation in Binge‐Eating Disorder

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective The interplay between the gut microbiome and autonomic nervous system remains unexplored in binge‐eating disorder (BED). We aimed to explore specific microbial alterations in BED and examine their potential association with cardiac vagal tone as a distinct bio‐behavioral phenotype.
Shuang Liang, Esben Strodl, Leanne Barron, Matthew Bambling, Luis Vitetta   +4 more
wiley   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

Epilepsia, EarlyView.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin, Hui‐Min Huang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Dual role of spreading depolarization in an epileptic focus

Epilepsia, EarlyView.
Abstract Objective Spreading depolarizations (SDs) are often associated with epileptic discharges. Although SDs are traditionally thought to contribute to postictal depression and termination of epileptic discharges, seizures may also occur during SDs or may even follow SDs, suggesting that interactions between SD and seizures are more complex.
Daria Vinokurova, Karina Tukhvatullina, Roustem Khazipov, Azat Nasretdinov   +3 more
wiley   +1 more source

An n‐of‐1 gene‐directed drug repurposing trial for an ultrarare genetic condition

Epilepsia, EarlyView.
Abstract Objective Gain‐of‐function (GoF) variants in the KCNC1 potassium channel subunit gene (Kv3.1) cause motor/cognitive delays and hypotonia and have been associated with seizures. Fluoxetine has inhibitory effects on Kv3.1. However, open‐label nonrandomized administration is insufficient to guide clinical decision‐making in ultrarare conditions ...
Vedika Jha, Christina Tsetsos, Mark Bedford, Gregory Costain, Sunita Vohra, Juan Pablo Diaz Martinez, Elise Heon, Jacob Vorstman, Carolina Gorodetsky, Ajoy Vincent, Jesiqua Rapley, Lori Anderson, Evdokia Anagnostou, Danielle A. Baribeau   +13 more
wiley   +1 more source

Three-arm randomised controlled trial of text message reminders and financial incentives to improve antidepressant adherence among adults in primary care with depression: study protocol. [PDF]

BMJ Open
Marcus SC, Bowden CF, Lynch KG, Olfson M.   +3 more
europepmc   +1 more source

Antidepressant poisoning [PDF]

Clinical Medicine, 2003
H K Ruben, Thanacoody, Simon H L, Thomas
openaire   +2 more sources